{"id":"W2810290010","doi":"10.1002/jbmr.3475","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Bone and Mineral Research","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":340,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Kyowa Hakko Kirin; Ultragenyx Pharmaceutical","keywords":"Hypophosphatemia; Placebo; Medicine; WOMAC; Internal medicine; Osteomalacia; Gastroenterology; Placebo-controlled study; Osteoarthritis; Surgery; Double blind; Vitamin D and neurology; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1118705389074112,"score_gpt":0.4582421274353874,"score_spread":0.3463715885279762,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}